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HIGHLIGHTS 
 Phylogenetic analysis of resistance in cystic fibrosis P. aeruginosa.  
 AmpC variations are associated with high-level cloxacillin-insensitive ceftazidime 
resistance. 
 AmpD variations are associated with ceftolozane/tazobactam and 
ceftazidime/avibactam double resistance. 
 Mutational resistance emerged in phylogenetically separate lineages. 
 Mutation-driven evolution in the population structure of P. aeruginosa. 
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ABSTRACT 
Pseudomonas aeruginosa is one of the most important pathogens in cystic fibrosis. In this 
study we analysed the genetic basis and phylogenetic profile of resistance to 
ceftazidime/avibactam and ceftolozane/tazobactam as well as carbapenems in cystic fibrosis 
P. aeruginosa isolates. We conducted whole genome sequence analysis of a collection of 
isolates resistant to piperacillin/tazobactam from seven hospitals in Scotland since the 
introduction of these two cephalosporin/β-lactamase inhibitor combinations. Ceftazidime 
resistance was primarily related to AmpC induction, as tested by cloxacillin inhibition assays, 
while amino acid variations in AmpC were associated with high-level ceftazidime resistance 
not reversed by cloxacillin. Only isolates resistant to both ceftazidime/avibactam and 
ceftolozane/tazobactam carried AmpD mutations, likely resulting in ampC overexpression. 
All isolates resistant to ceftazidime/avibactam and/or ceftolozane/tazobactam were resistant 
to carbapenems and showed inactivating mutations in the chromosomal oprD gene. None of 
the isolates bore class A, B, D plasmid-encoded carbapenemases. Critically, we show that 
mutational resistance emerged in phylogenetically distant lineages suggesting that the 
mutations occur independently without conferring a selective advantage to any phylogenetic 
lineage. Our findings confirm the strong contribution of mutation-driven evolution to the 
population structure of P. aeruginosa.  
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1. INTRODUCTION 
Pseudomonas aeruginosa remains one of the most important pathogens in cystic fibrosis.  
Being the biggest cause of morbidity and mortality in cystic fibrosis patients, P. aeruginosa 
status determines choices of prophylactic therapy as well as the treatment of pulmonary 
exacerbations (1, 2). Ceftazidime/avibactam and ceftolozane/tazobactam are 
cephalosporin/β-lactamase inhibitor combinations that have shown increased activity against 
P. aeruginosa in large multicentre studies (3, 4) and are now recommended in the UK as 
second line treatment for exacerbation of pulmonary infections where multidrug resistant 
strains are suspected. 
Resistance to cephalosporins in P. aeruginosa is mainly related to chromosomally-encoded 
ampC. AmpC-mediated resistance may be non-mutational as a result of AmpC induction (5). 
However, the most commonly described mechanism of resistance to newer cephalosporins 
involves mutational derepression of ampC (6). In addition to ampC itself, genes involved in 
ampC overexpression include the ampC regulator ampR, ampD (amidase), ampG 
(muropeptide permease) and dacB (encoding PBP4) (7-10). On the other hand, resistance 
to ceftazidime/avibactam and ceftolozane/tazobactam requires deletions and mutations 
leading to structural modifications in AmpC, respectively (11, 12). Notwithstanding the higher 
stability of ceftolozane to hydrolysis by β-lactamases compared to piperacillin, variants of the 
Pseudomonas-derived cephalosporinase (PDC) have been associated with resistance to 
ceftolozane/tazobactam (13).  AmpC derepression is also important for carbapenem 
resistance together with inactivation of porin protein D (OprD) (14). The efflux pump system 
MexAB-OprM has also been implicated in resistance to newer cephalosporins while MexXY-
OprM is thought to exhibit a preferential role in resistance to carbapenems (15).  
Development of multidrug resistance in P. aeruginosa lung isolates from cystic fibrosis 
patients has been mainly attributed to its ability to adapt to the cystic fibrosis airway 
microenvironment by multiple genotypic changes, hence the emphasis on intra-patient 
evolutionary isolate analyses (16). However, its ability to develop mutational resistance in 
the context of high selective pressure is also well known (17). 
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In this study we analysed the genetic basis and phylogenetic profile of resistance to 
ceftazidime/avibactam and ceftolozane/tazobactam as well as carbapenems in cystic fibrosis 
P. aeruginosa. The study focussed on a collection of multidrug resistant isolates from seven 
hospitals in Scotland since the introduction of these two cephalosporin/β-lactamase inhibitor 
combinations. 
2. METHODS 
2.1 Isolates 
This study involved the analysis of twenty-four Pseudomonas aeruginosa received by the 
Cystic Fibrosis Antibiotic Susceptibility Testing Service (CFASS) at Aberdeen Royal 
Infirmary from four hospitals across Scotland. This nationally funded service performs 
antibiotic combination testing on multidrug resistant Gram-negative isolates from adult cystic 
fibrosis patients around Scotland. Isolates were purified and identified from sputum between 
May 2015 and November 2016. Isolates cultured from clinical samples received by the 
Medical Microbiology laboratory at Aberdeen Royal Infirmary underwent initial cytochrome C 
oxidase testing and were then formally identified using an automated mass spectrometry 
microbial identification system (VITEK® MS, Biomerieux, Marcy-l'Étoile, France ). Isolates 
were randomly selected from our collection of piperacillin-tazobactam resistant isolates 
collected over the time period (resistance defined according to the EUCAST Clinical 
Breakpoint) and represented 31% of these isolates. Isolates 1600/1655, 1617/1618/1619 
and 1663/1664 were from the same patient. Analysis focussed on piperacillin-tazobactam 
resistant isolates as piperacillin-tazobactam is the standard antipseudomonal agent used in 
Scottish hospitals, hence the anticipated higher multidrug resistance rates in such isolates. 
 
2.2 Antimicrobial susceptibility testing and AmpC induction. 
Isolates were cultured on Mueller-Hinton agar plates (Oxoid, Thermo Fisher Scientific, 
Loughborough, UK) and incubated aerobically at 37°C for 24 hours. From overnight culture, 
a suspension in normal saline (0.9%) was prepared for each isolate to reach a turbidity 
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equivalent to that of a 0.5 McFarland standard. The suspension was re-inoculated onto 
Mueller-Hinton agar plates to obtain a lawn culture. E-test strips (BioMérieux) of selected 
antimicrobial agents (ceftazidime, ceftazidime/avibactam, piperacillin/tazobactam, 
ceftolozane/tazobactam, ceftobiprole, imipenem, meropenem) were then placed on the 
plates which were incubated aerobically at 37°C for 24 hours. E-test MICs values for each 
antimicrobial agent were interpreted according to EUCAST 2018 breakpoint values. The 
inhibition zone was read from the edge of the strip showing no growth when viewed from the 
back of the plate against a light source.   
To identify AmpC overproducers, Mueller-Hinton agar plates were prepared incorporating 
1000 mg/L of cloxacillin in sterile agar media. The suspension with 0.5 McFarland standard 
for each isolate was inoculated on these plates. An E-test strip (BioMérieux, Marcy-l'Étoile, 
France) containing ceftazidime was placed in each plate and incubated at 37°C for 24 hours. 
Isolates were considered AmpC overproducers when ceftazidime MIC values decreased by 
at least two dilutions on Mueller-Hinton supplemented with cloxacillin (PMID: 19738025).  
 
2.3 DNA extraction and sequencing 
For RNA-free genomic DNA extraction, a single colony was sub-cultured in nutrient broth 
(Oxoid, Thermo Fisher Scientific, Loughborough, UK) and incubated aerobically at 37°C for 
24 hours. Bacterial pellets were obtained by centrifuging 5 mL of an overnight bacterial broth 
culture for 5 minutes at 12,000–16,000 g. DNA was extracted using GenElute™ Bacterial 
Genomic DNA Kit (Sigma-Aldrich Company Ltd., Dorset, UK) following manufacturer’s 
instructions. DNA was quantified using Nano Drop Spectrophotometer disclosing 260/280 
and 260/230 ratio values within the normal limits (Thermo Fisher Scientific). All samples ran 
on 0.7% agarose gel yielded distinct bands with no smearing. DNA samples were further 
purified using AMPure beads (Beckman Coulter, Brea, CA, USA). 
Purified DNA was quantified using PicoGreen (Thermo Fisher Scientific) on the FLUOstar 
OPTIMA plate reader (BMG LABTECH Ltd. Bucks, UK). Input material was normalised to 
500 ng prior to fragmentation and library preparation. Fragmentation was performed by 
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mechanical shearing to an average size of 350 bp using a MultiFunctional Bioprocessor 
(EpiSonic; amplitude 40, process time 3min 20sec, pulse on/off 20sec). Library preparation 
was performed using the NEBNext Ultra DNA library prep kit for Illumina (New England 
Biolabs) and standard Illumina multiplexing adapters with minor modifications to 
manufacturer’s protocol. Libraries were PCR amplified (10 cycles) on a Tetrad (Bio-
Rad) using in-house unique dual indexing primers as described previously (18). Post-PCR 
purification performed using Agencourt Ampure XP (Beckman Coulter; ratio 1:0.75). 
Individual libraries were normalised using PicoGreen (Thermo Fisher). Individual libraries 
were normalised and pooled together accordingly. The size profile of the pooled library was 
analysed on the 2200 or 4200 TapeStation. The pooled library was quantified using Qubit 
(Invitrogen) and diluted to ~10 nM for storage. The 10 nM library was denatured and further 
diluted prior to loading on the sequencer. Paired-end sequencing was performed using a 
HiSeq4000 150bp platform (Illumina, HiSeq 3000/4000 PE Cluster Kit and 300 cycle SBS 
Kit). 
 
2.4. Genome assembly 
The adapters and poor quality bases were removed from short paired-end reads using 
Trimmomatic (version 0.36) and trimmed reads were used for sequence assembly using the 
de novo assembly algorithm, SPAdes (version 3.9.0). The quality of the assembled genome 
was analysed using the program QUAST (version 4.3). The minimum size of output 
contiguous sequences (contigs) was 200 bp. We found one sample with a high number of 
contigs. This outlier has not been included in the following summary statistics. The average 
number of contigs for genomes sequenced in this study was 128 with an average total 
assembled genome size of 6,444,512 bp and an average N50 length of 178,878 bp and with 
a 110× depth coverage. Assembly statistics of genome sequences are shown in 
Supplementary Table S1. 
 
2.5 Whole genome sequencing analysis 
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The draft genome was annotated using Prokka (version 1.11) and the accessory and core 
genes were identified by Roary (version 1.007001) using 80% of identity blastp. All core 
genes were aligned gene-by-gene using Muscle (version 3.8.31) and then concatenated 
using a custom script. The concatenated alignment was used to generate a ML core genome 
phylogenetic tree with a GTR model with gamma distribution of rate heterogeneity (GTR+G) 
using RAxML (version 8.2.12), and the pairwise SNP matrix was obtained with the program 
snp-dists version 0.6. The ggtree’s version 1.13.1 R package was used for the visualization 
of the phylogenetic tree with integrated antimicrobial susceptibility data. The presence of 
resistant genes was scanned in the contigs in multifasta format using the program ABRicate 
version 0.8, which uses the database NCBI, resfinder and CARD, by setting identity at 80% 
in the blast. For the identification of single nucleotide polymorphisms (SNPs) in candidate 
genes, the trimmed reads were mapped to the PAO1 reference genome (NC_002516.2) 
using BWA-MEM (maximal exact match) (version 0.7.16a-r1181) with default parameters. 
SAM file-to-BAM file conversion was performed using SAMtools (version 1.3.1). SNPs and 
insertions or deletions (indels) were called using mpileup from Samtools and vcftools 
(version 0.1.15). The effect of the genetic variants (stop codon, missense or frameshift) was 
studied using SnpEff (version 4.3t). Additionally, predictive analyses of the impact of amino 
acid changes on gene functions were carried out using the PROVEAN web server tool which 
scores the impact as deleterious or neutral. The NCBI GenBank Bioproject ID for the 
genome data is PRJNA507097 (Table S1).  
3. RESULTS AND DISCUSSION 
3.1 Clonal structure 
We have investigated a collection of twenty-four P. aeruginosa isolates from cystic fibrosis 
patients in Scotland selected on the basis of resistance to standard antipseudomonal agent 
piperacillin-tazobactam. Sequence typing and whole genome phylogenetic analysis shows 
isolate distribution over many lineages with few small clusters (Figure 1) (Table S1). Three of 
these clusters (1600/1655, 1617/1618/1619, 1663/1664) contained isolates from the same 
patient. Isolates 1600 and 1655 showed 29 SNPs between their core genomes (4,493 
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genes), while 1617, 1618, 1619 differed by 132 to 409 SNPs and 1663, 1664 by 282 SNPs. 
These differences are in line with intra-host evolution of P. aeruginosa clones during long-
term carriage (19). Other strains co-localising on the phylogenetic tree included 1608/1622 
(397 SNPs), 1442/1653/1713 (447, 937 and 1039 SNPs) and 1671/1689 (497 SNPs) but 
were all from unrelated patients. 
 
3.2 Susceptibility to ceftazidime/avibactam and ceftolozane/tazobactam 
Twenty out of the twenty-four isolates were resistant to ceftazidime and twelve were 
resistant to ceftazidime/avibactam and/or ceftolozane/tazobactam. None of the isolates 
resistant to ceftazidime/avibactam and ceftolozane/tazobactam were susceptible to 
carbapenems. All isolates were also resistant to ceftobiprole and piperacillin/tazobactam.  
Notwithstanding the limited diversity captured in this study focussed on 
piperacillin/tazobactam resistant isolates only, the proportion of ceftazidime/avibactam 
resistant isolates (37.5%) was not higher than that reported by a review of overall activity of 
ceftazidime/avibactam against UK P. aeruginosa isolates where 56.7% of 410 multidrug 
resistant and non-carbapenemase/non-ESBL-producing P. aeruginosa isolates were 
resistant to ceftazidime/avibactam (20). Our data would suggest an at least equal 
ceftazidime/avibactam activity against cystic fibrosis multidrug resistant isolates. However, 
we found a higher proportion of isolates resistant to ceftolozane/tazobactam (37.5%) 
compared to the resistance rate to ceftolozane/tazobactam reported for the collection of 
isolates aforementioned (18.4%) (20). A more recent study targeted to 43 cystic fibrosis P. 
aeruginosa isolates shows even lower resistance rates to ceftolozane/tazobactam (4.3%), 
although the majority of the isolates included in this study were susceptible to meropenem 
(76.6%) (21).  
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3.3 Determinants of resistance to ceftazidime/avibactam and 
ceftolozane/tazobactam 
We performed ceftazidime susceptibility testing in the presence of cloxacillin to identify 
AmpC overproducers amongst isolates resistant to ceftazidime, ceftazidime/avibactam 
and/or ceftolozane/tazobactam. Ceftazidime MIC reduction in the presence of cloxacillin was 
observed in 15 out of the 20 ceftazidime-resistant isolates (Table 1) suggesting that AmpC 
overproduction was the predominant resistance mechanism. AmpC missense mutations 
(A31V, Q155R, Q157R, V239T, V239A, G242D, G248S, S306T) were present in four out of 
the five isolates, the ceftazidime MIC of which was not inhibited by cloxacillin. Of the 
aforementioned mutations, Q157R and G248S have been described previously (11, 22, 23). 
Notably, variations in amino acid V239 occurred in multiple unrelated isolates. The ampC 
missense mutation T105A was present in 21 isolates but not associated with any resistance 
profile (data not shown). The contribution of T105A to extended-spectrum AmpC β-
lactamase activity (ESAC) was suggested (24), but subsequently not confirmed (6). We 
speculate that missense mutations in ampD, ampG and dacB may contribute to ceftazidime 
resistance in isolate 1631 where ampC mutations were absent (Table 1). AmpC deletions 
previously associated with ceftazidime/avibactam resistance (12) were not detected in any of 
the isolates. 
To further investigate molecular mechanisms of ceftolozane/tazobactam and/or 
ceftazidime/avibactam resistance we analysed mutations in ampR (ampC regulator), ampD 
(amidase), ampG (muropeptide permease), mexR (MexAB/OprM regulator)  and dacB 
(encoding PBP4), all previously associated with ampC overexpression (8-10) (Table 1). All 
six double resistant isolates to both ceftolozane/tazobactam and ceftazidime/avibactam had 
ampD mutations - four isolates showed frameshifts and one isolate bore the H157R active 
site mutation (22, 25). Importantly ceftazidime resistance in all these isolates was not 
inhibited by cloxacillin, and it is therefore likely related to constitutive AmpC overproduction, 
in turn potentially driven by AmpD activity. 
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There was no definitive association with any particular mutations for the six isolates that 
were resistant to either ceftolozane/tazobactam or ceftazidime/avibactam. The three 
ceftazidime/avibactam resistant isolates showed ampR and mexR mutations (Table 1). We 
observed a total of six ampR missense SNPs - D135N (isolate 1713) and R86C (isolate 
1663) were shown to contribute to upregulation of ampC in P. aeruginosa (11) and 
Enterobacter cloacae (26), respectively, while no role has been documented for A81S and 
A227V (Table 1). We have detected AmpR mutations M288R and G283E but omitted these 
from Table 1 as they are inconsequential to ampC expression (27).  
Analyses of mexR, regulator gene of the MexAB/OprM ceftazidime-related efflux system, 
disclosed the following amino acid variations (Table 1): in-frame deletion R73-R82del,  
missense mutation A66V, the R83C mutation involved in DNA binding (28),  frameshift 
G77fs and the V126E mutation (not shown) which plays no role in ceftazidime resistance  
(29).  MexR in-frame deletion R73-R82del was observed in isolate 1638 which showed a 
MIC of 6 μg/ml for both ceftazidime/avibactam and ceftolozane/tazobactam as well as 
ceftazidime alone. Amongst the ceftolozane/tazobactam and/or ceftazidime/avibactam 
resistant isolates dacB mutations were only observed in isolate 1631, the only isolate without  
variations in AmpC where ceftazidime resistance was not reversed by cloxacillin (Table 1). 
Figure 1 shows the carriage profile of PDC β-lactamases (24) in this collection of isolates. 
PDC-3 was the most prevalent variant but none of the PDC-3 mutations associated with 
ceftolazone/tazobactam resistance (13) were observed. 
Frameshift mutations in the MexXY regulator gene mexZ associated with resistance to 
ceftobiprole (30) were observed in nine isolates (Supplementary Table S2). However, all the 
isolates analysed in this study were ceftobiprole resistant regardless of the presence of 
mexZ mutations (Supplementary Table S2).  
 
3.4 Genetic determinants of carbapenem resistance 
Susceptibility to carbapenems is summarised in Table 1. Nineteen out of twenty-four isolates 
tested (79%) were resistant to meropenem and/or imipenem. Whole genome analysis using 
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the Abricate software, based on both the NCBI and CARD antimicrobial resistance gene 
databases, showed no evidence of carbapenemase genes in any of the isolates. All thirteen 
meropenem-resistant isolates (MIC >32 mg/L) showed either a frameshift or a stop codon in 
the oprD porin gene. This is consistent with other data showing that oprD mutations are a 
major mechanism of meropenem resistance in the UK (20). OprD missense mutations G55D 
(isolate 1442) and S278P (isolate 1631), the latter of which has been reported previously 
(31), were unique to these two imipenem/meropenem double -resistant isolates, although 
oprD frameshifts were also present in both cases (Table 1). Two identical SNPs were 
observed in different isolates, one of which (Q402fs) surprisingly occurred independently in 
two isolates 1638 and 1664 belonging to separate phylogenetic lineages (ST379 and ST885, 
respectively, Table1 and Figure 1). Six out of the eleven meropenem-sensitive isolates 
showed resistance to imipenem. Five of these six isolates showed intermediate susceptibility 
to meropenem but only two out of the six had frameshifts in oprD (P220fs and Q402fs) 
(Table 1). OprD missense mutations were not detected in the six imipenem-resistant 
meropenem-sensitive isolates.  
The mexT gene was analysed in view of its role in negative regulation of oprD expression 
(32). Variations in MexT were seen in three carbapenem-resistant isolates that were also 
resistant to ceftozolane/tazobactam. However, all three isolates bore a frameshift in oprD, 
drawing uncertainty on the role of mexT (Table 1).  
 
3.5 Resistance due to horizontal gene transfer 
We identified only one mobile genetic element associated with resistance in three isolates 
from the same patient (1617, 1618, 1619). However, this class I integron carried only the 
aminoglycoside adenyltransferase gene aadA1, the sulphonamide resistance gene sul1 and 
the efflux pump gene qacΔE, all of which are irrelevant to β-lactam resistance. It is important 
to highlight that none of the isolates bore class A, B, D plasmid-encoded carbapenemases, 
the carriage rate of which is notoriously lower in UK P. aeruginosa isolates as compared to 
Enterobacteriaceae (20). 
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4. CONCLUSIONS 
Analyses of this collection of piperacillin/tazobactam cystic fibrosis P. aeruginosa isolates 
shows frameshifts and stop codons in oprD as the main mechanism of carbapenem 
resistance. AmpC induction was the most frequent mechanism of ceftazidime resistance, 
while amino acid variations in AmpC were associated with high-level ceftazidime resistance 
not reversed by cloxacillin. AmpC mutational derepression was likely associated with double 
resistance to ceftolozane/tazobactam and ceftazidime/avibactam in view of ampD missense 
mutations present only in these isolates. Importantly, we showed that these mutations occur 
independently without seeming to confer a selective advantage to any phylogenetic lineage. 
This is supported by the emergence of mutations (in some cases identical) in 
phylogenetically distant lineages against a backdrop of phenotypic variations in sequential 
isolates from the same patient. These observations confirm the strong contribution of 
mutation-driven evolution to the population structure of P. aeruginosa (17). 
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FIGURE LEGEND 
 
Figure 1: Core genome phylogenetic tree of Scottish P. aeruginosa isolates from 
cystic fibrosis. The core genome phylogenetic tree was generated using RAxML on 4,493 
genes. The sequence type (ST) and the PDC variant (Pseudomonas-derived 
cephalosporinase) of all twenty-four isolates is shown along with reference strain PAO1 
(NC_002516.2). The antimicrobial resistance phenotypes are shown in the heat map to the 
right (black = resistant, grey = susceptible). Isolates from the same patient are highlighted in 
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blue. The scale bar shown at the bottom left of the figure indicates the average number of 
substitution per site. 
 
Table 1: Resistance-related phenotypes and genotypes in P. aeruginosa isolates 
isol
ate 
S
T 
ceftaz
idime 
ceftaz
idime 
cloxac
illin 
ceftol
ozane 
tazob
actam 
ceftaz
idime 
aviba
ctam 
am
pC 
am
pR 
am
pD 
am
pG 
me
xR 
dacB 
im
ip
en
em
 
m
er
o
p
en
e
m
 opr
D 
me
xT 
1442 17 2 1.5 2 8       
>3
2 
>3
2 
G55D 
(n), 
Val12
7fs(d)  
 
1472 
34
8 
2 3 0.75 3       
>3
2 
4   
1463 
25
2 
3 0.75 2 2       
>3
2 
0.
25 
  
1638 
37
9 
6 6 6 6     
R73-
R82d
el(d) 
 
>3
2 
>3
2 
Q402f
s(d) 
 
1510 
58
4 
12 1.5 0.38 0.5       1 
1.
5 
  
1618 
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10 
12 3 0.70 4     
G77f
s 
 1 4   
1655 
13
2 
16 2 3 3       4 
0.
75 
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32 8 1.5 24  
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(d) 
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>3
2 
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s(d) 
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>3
2 
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1713 17 48 3 4 1  
D135
N(d); 
A227
V(d) 
    16 6 
P220f
s(d) 
 
1600 
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2 
96 0.13 3 1.5       1 
0.
25 
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84
5 
96 6 0.75 2  
A81S
(n) 
    
>3
2 
6   
1608 
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256 0.5 1 1       
>3
2 
>3
2 
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stop 
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256 2 0.5 0.5       2 1   
1590 
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256 8 6 12   
H15
7R(d
) 
   
>3
2 
>3
2 
W277
stop 
V57I(
n) 
1658 
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6 
256 32 32 12   
D105
fs(d) 
 
R83C
(d) 
 
>3
2 
>3
2 
N262f
s(d) 
M7V
(n) 
1631 
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6 
256 256 256 256   
T7A(
n) 
W33
6R(n) 
 
P331L(n),
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>3
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>3
2 
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S278P
(d) 
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256 256 256 256 
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T (d), 
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T(n) 
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s(d) 
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R(n) 
  
>3
2 
>3
2 
F69fs(
d) 
 
1664 
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5 
256 256 12 8 
A31V
(n); 
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A(d); 
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S(n) 
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2 
2 
Q402f
s(d) 
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V(d), 
G300
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S346
R(n) 
1671 25 256 256 256 256 Q157  F172    >3 >3 G152f  
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70 R(n); 
V239
A(d); 
G248
S(n) 
fs(d) 2 2 s(d) 
1689 
25
70 
256 256 256 256 
 
V239
A(d) 
 
F172
fs(d) 
   
>3
2 
>3
2 
G152f
s(d) 
 
Grey shading for MICs above the respective breakpoints. Only ampC, ampD, ampG, and dacB 
variations potentially relevant to ceftolozane/tazobactam and/or ceftazidime/avibactam resistance 
are shown. Findings of predictive functional analyses using PROVEAN are shown in brackets 
(n=neutral; d=deleterious).  
 
 
